D. Boral Capital Reiterates Buy Rating for Clene (NASDAQ:CLNN)

Clene (NASDAQ:CLNN)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $23.00 price target on the stock. D. Boral Capital’s price target points to a potential upside of 285.26% from the company’s current price.

A number of other research analysts also recently commented on CLNN. UBS Group reaffirmed a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Benchmark reaffirmed a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a report on Tuesday, October 14th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $32.60.

Clene Stock Performance

Shares of NASDAQ CLNN opened at $5.97 on Friday. The firm has a market cap of $61.67 million, a P/E ratio of -1.76 and a beta of 0.87. Clene has a 1 year low of $2.28 and a 1 year high of $13.50. The firm’s 50 day moving average price is $7.80 and its 200 day moving average price is $6.39.

Clene (NASDAQ:CLNN) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. As a group, equities analysts predict that Clene will post -5.19 EPS for the current year.

Insider Activity

In other news, major shareholder Chidozie Ugwumba sold 5,869 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $5.87, for a total value of $34,451.03. Following the transaction, the insider owned 760,611 shares of the company’s stock, valued at approximately $4,464,786.57. This trade represents a 0.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 321,677 shares of company stock valued at $2,113,866 over the last ninety days. 35.30% of the stock is owned by corporate insiders.

Institutional Trading of Clene

Several large investors have recently added to or reduced their stakes in CLNN. Jones Financial Companies Lllp acquired a new position in shares of Clene during the third quarter worth about $29,000. Jane Street Group LLC acquired a new stake in Clene in the second quarter valued at approximately $47,000. Lunt Capital Management Inc. raised its stake in shares of Clene by 71.2% during the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after purchasing an additional 21,217 shares during the period. Finally, Scoggin Management LP raised its stake in shares of Clene by 42.8% during the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after purchasing an additional 42,750 shares during the period. 23.28% of the stock is currently owned by institutional investors and hedge funds.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).